Searchable abstracts of presentations at key conferences in endocrinology

ea0035p1067 | Thyroid (non-cancer) | ECE2014

Successful preoperative treatment of toxic nodular goiter patient with agranulocytosis using plasmapheresis

Trybek Tomasz , Kowalska Aldona

Agranulocytosis is an uncommon but very serious complication during treatment with thyrostatic. In case of severe hyperthyroidism removal of circulating thyroid hormones by plasmapheresis may be an effective therapeutic option.We present the therapeutic difficulties and successful treatment with preoperative plasmapheresis in 63-year-old female patient with severe hyperthyroidism in the course of toxic nodular goiter and agranulocytosis, which occurred a...

ea0041gp227 | Thyroid Cancer | ECE2016

Is ultrasensitive Tg measurement capable of substituting for Tg measurement after rhTSH stimulation in evaluation of effectiveness of radioiodine ablation in patients with differentiated thyroid cancer

Kowalska Aldona , Gasior-Perczak Danuta , Palyga Iwona , Trybek Tomasz , Sluszniak Anna

Introduction: Undetectable concentration of Tg after rhTSH stimulation (Tg/rhTSH) is one of the most important criteria in evaluating the effectiveness of radioiodine ablation in patients with differentiated thyroid cancer (DTC) treated with 131I.Aim: To evaluate the possibility of using L-T4 suppression treatment (Tg/L-T4) measurements by the ultrasensitive method TRACE (immunofluorescence method) with the KRYPTOR analyzer instead of the Tg/rhTSH measur...

ea0049ep1274 | Thyroid (non-cancer) | ECE2017

Is there a correlation between serum selenium level and the severity of Graves’ orbitopathy?

Palyga Iwona , Gasior-Perczak Danuta , Gadawska-Juszczyk Klaudia , Mikina Estera , Piwowar Monika , Szymonek Monika , Trybek Tomasz , Walczyk Agnieszka , Mezyk Ryszard , Majewska Urszula , Kowalska Aldona

Introduction: Selenium (Se) deficiency is a known risk factor for autoimmune thyroid diseases including Graves’ orbitopathy (GO).Objective: To determine the concentration of Se in serum and to determine the dependency of Se concentration on known markers of disease severity: the TRAB levels and the CAS (clinical activity score) in patients with GO.Material: 64 patients (50 women, 14 men; average age- 54.5 years) with active, m...

ea0041ep1053 | Thyroid (non-cancer) | ECE2016

Can routine steroid cover during radioiodine therapy of patients with Graves’ disease (GD) prevent the onset of de novo Graves’ orbitopathy (GO)?

Kowalska Aldona , Palyga Iwona , Gasior-Perczak Danuta , Mikina Estera , Szymonek Monika , Piwowar Monika , Gadawska-Juszczyk Klaudia , Trybek Tomasz , Mezyk Ryszard , Gozdz Stanislaw

Introduction: Radioiodine therapy is considered as a risk factor for the development of Graves’ orbitopathy (GO) de novo or worsening of pre-existing orbitopathy. This risk is estimated in the available literature as up to 15–20%. Steroid cover is considered to eliminated this risk.Objective: The aim of our study was to established the relationship between the occurrence of GO and treatment with radioiodine. And the analysis of the time of appe...

ea0063gp82 | Thyroid Nodules and Cancer | ECE2019

Coexistence of the BRAF V600E and TERT promoter mutations and their impact on response to therapy and final outcome of papillary thyroid cancer

Trybek Tomasz , Walczyk Agnieszka , Gęsior-Perczak Danuta , Pałyga Iwona , Mikina Estera , Kowalik Artur , Kopczyński Janusz , Chrapek Magdalena , Goźdź Stanisław , Kowalska Aldona

Introduction: Coexistence of the BRAF V600E and TERT promoter mutations may correlate with more aggressive histopathological features and worse course of the disease. According to the American Thyroid Association (ATA) dynamic risk stratification with modified initial estimated risk based on response- to-therapy and disease course allows individual risk assessment and support clinicians in the appropriate management approach to differentiated thyroid cancer (...